Oral etoposide in relapsed or refractory Ewing sarcoma: a monoinstitutional experience in children and adolescents

Tumori
Marta G PoddaMaura Massimino

Abstract

To assess the efficacy and toxicity of low-dose oral etoposide (VP) 16 in relapsing/refractory Ewing sarcoma. The records of all patients treated at our department between 1989 and 2012 for relapsing/refractory Ewing sarcoma who received oral VP-16 were analyzed. The dose was 40 mg/m2 daily for 21 consecutive days in every 28. Response was assessed after 2/3 cycles according to Response Evaluation Criteria in Solid Tumors 1.0. A total of 46 of 58 patients completed at least 2 cycles; 12 suspended the treatment earlier due to rapid disease progression. The patients' median age at diagnosis was 14 years and 25/58 had metastatic disease. All patients received intensive polychemotherapy including VP-16 IV as first- (n = 53) or second-line (n = 5) treatment; 21/58 had myeloablative regimens with peripheral blood stem cell rescue, and 1 underwent allogeneic stem cell transplantation. Oral VP-16 was prescribed as 2nd-, 3rd-, and 4th-line treatment for 19, 27, and 12 patients, respectively. The cycles administered totaled 241 (median 3, mean 4 per patient; range 1-14). A total of 46 of 58 patients were evaluable: 11 responded (9 partial remission, 1 very good partial remission, 1 complete remission) and 10 were stable, the response las...Continue Reading

References

Sep 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M L SlevinP F Wrigley
Jan 1, 1987·Cancer Chemotherapy and Pharmacology·S N WolffK R Hande
Jul 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P I ClarkP F Wrigley
Jan 1, 1994·Medical and Pediatric Oncology·M GaspariniF Fossati-Bellani
Jun 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D M AshleyD Longee
Apr 1, 1997·Journal of Child Neurology·M C Chamberlain
Oct 3, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B H KushnerN K Cheung
Mar 11, 2000·Drugs·R L ComisB C Good
Feb 18, 2004·Pediatric Blood & Cancer·Rejin KebudiInci Ayan
Mar 23, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lisa M BarkerDouglas S Hawkins
Sep 29, 2005·Journal of Pediatric Hematology/oncology·Alessandro SandriEnrico Madon
Mar 21, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Fariba NavidCarlos Rodriguez-Galindo
Jun 16, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ruth LadensteinHeribert Jürgens
Sep 25, 2014·Pediatric Hematology and Oncology·Nilgun KurucuInci Ergurhan Ilhan
Jan 15, 2015·Pediatric Blood & Cancer·Stefano FerrariAdalberto Brach del Prever

❮ Previous
Next ❯

Citations

Mar 23, 2017·Cancer·Damon R ReedMichael S Isakoff

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.